Compare · MDGL vs NVO
MDGL vs NVO
Side-by-side comparison of Madrigal Pharmaceuticals Inc. (MDGL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 17.1x MDGL ($11.23B).
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 22 for MDGL).
- Company
- Madrigal Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $467.16-4.07%
- $41.01-4.51%
- Market cap
- $11.23B
- $191.82B
- 1M return
- -12.71%
- -
- 1Y return
- +66.92%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 8
- 8
- Recent ratings
- 22
- 25
Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MDGL
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
- Chief Medical Officer Soergel David sold $516,561 worth of shares (1,042 units at $495.74) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,033 units (SEC Form 4)
- Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
- Director Levy Richard S sold $2,928,716 worth of shares (5,682 units at $515.44) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 22,015 units (SEC Form 4)
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
- Chief Medical Officer Soergel David sold $435,420 worth of shares (844 units at $515.90), decreasing direct ownership by 7% to 11,075 units (SEC Form 4) to satisfy tax liability
- Amendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care